Strategic partnership with Takara Bio Inc. for TK cell therapy

MolMed has signed a number of agreements with Takara Bio Inc., including a non-exclusive in-licensing agreement for Takara Bio’s RetroNectin for the EU and U.S., and an out-licensing and development agreement to conduct clinical studies and to market MolMed’s cell-based product TK in Asia. Takara Bio is the largest public Japanese biotech company (by market capitalisation), has specific expertise in the field of gene and cell therapy, and has affiliates in China and South Korea.


Agreement with the Telethon Foundation for co-development & clinical-grade manufacturing of gene therapies for six rare genetic diseases (see also GMP Platform)

MolMed considers of particular value the agreement signed in March 2011 with the Telethon Foundation, the most important private Italian research organisation, for:
• development of lentiviral vectors to be used in new gene therapy protocols for four rare genetic diseases
• manufacturing of patient-specific, genetically engineered cells used in gene therapy clinical trials for the treatment of metachromatic leukodystrophy (MLD) and Wiskott-Aldrich syndrome (WAS)

Agreement with the San Raffaele Foundation for the clinical-grade manufacturing of a cell therapy for Duchenne muscular dystrophy (see also GMP Platform)  

MolMed provides patient-specific mesangioblasts to be used in a clinical trial protocol for allogeneic cell therapy of Duchenne muscular dystropy. MolMed has also performed the development and scale-up of mesangioblast cell cultures, as part of the activities under the EU-FP7 co-funded project OPTISTEM.